Alcon stock gains 1.13 percent to EUR 57.38 after Q2 beat

Published on 09/29/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock was trading at EUR 57.38, up 1.13 percent versus the Xetra close of EUR 56.74 on September 28, 2026. Q2 core EPS reached USD 0.84, 9.09 percent above consensus.

Photorealistic wide panoramic view of a modern ophthalmic surgery operating room. Surgical microscope centered, sterile metallic instruments arranged on blue drape, scrub-suited surgical team in background, cold overhead surgical lighting — Alcon CH0432492467: Augenchirurgie OP Saal mit Mikroskop, sterilen Werkzeugen und einem Operationsteam, Illustration mit AI erstellt.

Alcon stock (ISIN CH0432492467) was trading at EUR 57.38 at Lang & Schwarz on September 29, 2026 at 1:30 p.m. CEST, up 1.13 percent versus the Xetra close of EUR 56.74 on September 28, 2026. The latest earnings update gives the move a concrete reference point: second-quarter core EPS reached USD 0.84, while sales rose to USD 2.78 billion, according to The Globe and Mail on August 11, 2026.

Q2 earnings beat expectations

The USD 0.84 core EPS result was 10.50 percent higher than a year earlier and 9.09 percent above the consensus estimate. Net sales increased 8.00 percent year over year and exceeded consensus by 0.58 percent, giving Alcon a stronger operating base despite pressure in parts of cataract care.

The segment detail matters. Surgical sales reached USD 1.57 billion, up 8.00 percent year over year, while Vision Care generated USD 1.21 billion, also up 8.00 percent. Equipment and other sales rose 25.00 percent to USD 279.00 million, while Ocular Health sales increased 12.00 percent to USD 486.00 million.

Guidance points to further growth

Alcon maintained its 2026 constant-currency sales growth outlook at 5.00 percent to 7.00 percent. It also raised its core diluted EPS growth guidance to 12.00 percent to 15.00 percent from the previous 10.00 percent to 13.00 percent range, according to the August 11, 2026 report.

For investors, the guidance change is more important than the headline sales beat because it raises the expected earnings trajectory while the company continues to absorb competitive pressure in implantables and softness in cataract procedures. Alcon's investor-relations page describes a portfolio spanning Surgical and Vision Care products across more than 140 countries, linking the quarterly result to two distinct growth engines.

Analyst target stays above market

Berenberg maintained a Buy rating on Alcon and set a CHF 85.00 price target in a report dated September 11, 2026, as reported by The Globe and Mail. The target is stated in Swiss francs for the SIX-listed share and is separate from the EUR 57.38 Lang & Schwarz indication.

Alcon stock trades at EUR 57.38

At Lang & Schwarz, Alcon stock was trading at EUR 57.38 on September 29, 2026 at 1:30 p.m. CEST. The price stood 1.13 percent above the Xetra close of EUR 56.74 from September 28, 2026. On the SIX Swiss Exchange, the share traded in CHF, with market capitalization at CHF 25.7 billion and a 52-week range of CHF 48.04 to CHF 68.27 on September 29, 2026.